Condition:   Severe Aortic Valve Stenosis
Intervention:   Device: Medtronic CoreValve System
Sponsor:   Medtronic Bakken Research Center
Not yet recruiting - verified March 2010

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin on background standard of care for diabetes;   Drug: Placebo on background standard of care for diabetes
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   George Institute, Sydney, Australia
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: questionnaire administration;   Procedure: cognitive assessment
Sponsor:   Medical Research Council
Recruiting - verified February 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Tiotropium 18mcg daily;   Drug: Salmeterol 100mcg daily;   Drug: Fluticasone 250mcg daily;   Drug: Fluticasone 125mcg daily;   Drug: Fluticasone 50mcg daily;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Bronchiectasis
Interventions:   Drug: Cipro (Ciprofloxacin, BAYQ3939);   Drug: Placebo
Sponsors:   Bayer;   Novartis
Recruiting - verified February 2010

Conditions:   Choroidal Neovascularization (CNV);   Age-related Macular Degeneration (AMD);   Early Markers
Intervention:   Other: no drug
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: MORAb-003 (farletuzumab);   Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
Sponsor:   Morphotek
Recruiting - verified October 2009

Conditions:   Metastatic;   Colorectal Cancer
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin);   Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified February 2010

Condition:   Cystic Fibrosis
Interventions:   Drug: Ataluren (PTC124);   Drug: Placebo
Sponsors:   PTC Therapeutics;   Genzyme;   Cystic Fibrosis Foundation
Recruiting - verified March 2010

Conditions:   Acute Lung Injury;   Acute Respiratory Distress Syndrome
Intervention:   Drug: Interferon Beta
Sponsor:   Faron Pharmaceuticals Ltd
Recruiting - verified March 2009

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ofatumumab (GSK1841157) infusion;   Drug: chlorambucil, tablets
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma;   Carcinoma, Hypernephroid
Interventions:   Drug: bevacizumab, RAD001(Everolimus);   Drug: bevacizumab, interferon alfa-2a
Sponsors:   Novartis Pharmaceuticals;   Roche Pharma AG
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified February 2010

Condition:   Alzheimer Disease
Interventions:   Drug: bapineuzumab;   Drug: placebo
Sponsor:   Wyeth
Recruiting - verified February 2010

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Myocardial Infarction
Interventions:   Drug: tenecteplase;   Drug: enoxaparin;   Drug: clopidogrel;   Procedure: catheterisation;   Procedure: primary PCI
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2010

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: Darbepoetin alfa
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Endocrine Tumors
Interventions:   Drug: lanreotide (Autogel formulation);   Other: Placebo
Sponsor:   Ipsen
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: celecoxib;   Drug: docetaxel;   Drug: prednisolone;   Drug: releasing hormone agonist therapy;   Drug: zoledronic acid;   Procedure: orchiectomy
Sponsor:   Medical Research Council
Recruiting - verified March 2008

Condition:   Heart Failure
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010